Drug Profile
Research programme: interferon beta-1b biosimilar - Biogenomics
Alternative Names: Recombinant IFN 1bLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Biogenomics
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Multiple-sclerosis in India (SC, Injection)
- 16 Jan 2014 Research programme: interferon beta-1b biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
- 16 Jan 2014 Early research in Multiple sclerosis in India (SC)